Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
13.30
-0.06 (-0.45%)
Jun 12, 2026, 4:00 PM EDT - Market closed
Dr. Reddy's Laboratories Revenue
In the fiscal year ending March 31, 2026, Dr. Reddy's Laboratories had annual revenue of 335.93B INR with 3.19% growth. Dr. Reddy's Laboratories had revenue of 75.46B in the quarter ending March 31, 2026, a decrease of -11.51%.
Revenue (ttm)
335.93B INR
Revenue Growth
+3.19%
P/S Ratio
3.12
Revenue / Employee
12,203,764 INR
Employees
27,527
Market Cap
11.16B USD
Revenue Chart
* This company reports financials in INR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 335.93B | 10.40B | 3.19% |
| Mar 31, 2025 | 325.54B | 46.37B | 16.61% |
| Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
| Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
| Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
| Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
| Mar 31, 2020 | 174.60B | 20.75B | 13.49% |
| Mar 31, 2019 | 153.85B | 11.82B | 8.32% |
| Mar 31, 2018 | 142.03B | 1.22B | 0.87% |
| Mar 31, 2017 | 140.81B | -13.90B | -8.98% |
| Mar 31, 2016 | 154.71B | 6.52B | 4.40% |
| Mar 31, 2015 | 148.19B | 16.02B | 12.12% |
| Mar 31, 2014 | 132.17B | 15.90B | 13.68% |
| Mar 31, 2013 | 116.27B | 19.53B | 20.19% |
| Mar 31, 2012 | 96.74B | 22.04B | 29.51% |
| Mar 31, 2011 | 74.69B | 4.42B | 6.28% |
| Mar 31, 2010 | 70.28B | 836.00M | 1.20% |
| Mar 31, 2009 | 69.44B | 19.44B | 38.87% |
| Mar 31, 2008 | 50.01B | -79.27B | -61.32% |
| Mar 31, 2007 | 129.28B | 80.94B | 167.42% |
| Mar 31, 2006 | 48.34B | 9.70B | 25.10% |
| Mar 31, 2005 | 38.65B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Viatris | 14.56B |
| Elanco Animal Health | 4.89B |
| United Therapeutics | 3.17B |
| Neurocrine Biosciences | 3.10B |
| Amneal Pharmaceuticals | 3.05B |
| Hims & Hers Health | 2.37B |
| Alkermes | 1.56B |
| Lantheus Holdings | 1.55B |
RDY News
- 5 hours ago - Dr. Reddy’s announces first-to-market launch of Bosutinib Tablets 400mg - TheFly
- 1 day ago - Dr. Reddy's Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States - Business Wire
- 1 day ago - Dr. Reddy's launches Bosutinib Tablets 400mg in the United States - Business Upturn
- 3 days ago - Nomura on Pharma May 2026: Torrent leads semaglutide with 19% market share, Sun gains; Alkem and Dr Reddy's lag market - Business Upturn
- 9 days ago - Dr. Reddy's Laboratories issues 12,100 equity shares under stock options scheme - Business Upturn
- 15 days ago - Dr. Reddy's files 20-F annual report with US SEC for fiscal year ended March 31, 2026 - Business Upturn
- 16 days ago - NYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoY - PRNewsWire
- 17 days ago - Dr Reddy’s to ring closing bell at NYSE to mark 25 years of its listing - The Times of India